STEM CELL TRANSPLANTATION for WALDENSTROM'S MACROGLOBULINEMIA (WM). UPDATED REPORT from the LYMPHOMA WORKING PARTY of the EUROPEAN SOCIETY for BLOOD and MARROW TRANSPLANTATION
No Thumbnail Available
Authors
Kyriakou C.
Fekom M.
Khvedelidze I.
Moukalled N.
Serroukh Y.
Castagna L.
Montoto S.
Saidy A.O.
Nguyen S.
Lung W.K.
Contact
Check for full-text access
Issue Date
2025
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: WM is rare low-grade B-cell lymphoplasmacytic lymphoma. In the era of novel therapies the role for high dose therapy followed by either autologous (ASCT) or allogeneic (alloSCT) haemopoietic stem cell transplantation (HSCT) at any point in the treatment pathway is debatable. Method(s): This EBMT registry retrospective analysis included patients with WM transplanted between 2000-2021 with complete data and excluded patients with high grade transformation. Result(s): 772 patients received ASCT. The median age was 57 years, 72% were male and the median time from diagnosis to AHSCT was 24 months. The number of prior lines therapy were, 1 in 24%, 2 in 39% and >=3 in 37% of the patients. Disease status at AHSCT was >=VGPR in 36%, PR in 52%, primary refractory (PR) or relapse refractory disease (PR/RD) in 12%. Karnofsky performance status (KPS) was =3 therapy lines, 21% failed previous ASCT prior to alloSCT. Disease status at the alloSCT was >=VGPR in 30%, PR in 45% and PRRD in 26%. KPS was 90 (p = 0.009), was associated with significantly better OS, whilst having PRRD status at alloSCT with worse OS (p = 0.017), PFS (p = 0.007) and RR rates (p = 0.023). HLA mismatched HSC donor type was associated with significantly higher incidence of cGVHD (p = 0.029). Conclusion(s): A high percentage of the included patients had at least 3 prior therapy lines and PR or PD at the time of SCT. This analysis suggests that selected transplant eligible patients with WM can be salvaged with SCT with acceptable survival and toxicity outcomes.
Description
Citation
Publisher
License
Journal
Bone Marrow Transplantation